[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339368-105":59,"doc-detail-339368-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dsrnai-mediated-silencing-of-pias2beta-specifically-kills-anaplastic-carcinomas-by-mitotic-catastrophe","dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe","","E3 SUMO ligase PIAS2 is abundant in differentiated papillary thyroid carcinomas but low in anaplastic thyroid carcinomas (ATC). Transcribed double-stranded RNA interference targeting the PIAS2β isoform (PIAS2b-dsRNAi) suppresses ATC cell growth in vitro and inhibits orthotopic patient-derived xenografts, without affecting normal or non-anaplastic thyroid cultures. The approach also reduces growth of other aggressive anaplastic human cancers. Mechanistically, PIAS2b loss triggers prophase mitotic catastrophe; proteomics identify PSMC5 and TUBB3 as SUMOylation targets at mitotic initiation, supporting PIAS2b-dsRNAi as a candidate therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dsrnai-mediated-silencing-of-pias2beta-specifically-kills-anaplastic-carcinomas-by-mitotic-catastrophe/339368/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dsrnai-mediated-silencing-of-pias2beta-specifically-kills-anaplastic-carcinomas-by-mitotic-catastrophe/339368.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the therapeutic target in this study?","Question",{"text":112,"@type":113},"The study targets the PIAS2β isoform using PIAS2b-dsRNAi to deplete PIAS2β in anaplastic thyroid carcinoma models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Does PIAS2b-dsRNAi affect normal or non-anaplastic thyroid cells?",{"text":117,"@type":113},"No. PIAS2b-dsRNAi does not affect growth of normal thyroid or non-anaplastic thyroid tumor cultures and cell lines in the reported results.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PIAS2b depletion kill anaplastic cancer cells mechanistically?",{"text":121,"@type":113},"PIAS2b depletion promotes mitotic catastrophe at prophase by disrupting proper mitotic spindle and centrosome assembly, with PSMC5 and TUBB3 identified as direct SUMOylation targets at mitotic initiation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339368,1790625385,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Article [https://doi.org/10.1038/s41467-024-47751-](https://doi.org/10.1038/s41467-024-47751-)  \ndsRNAi-mediated silencing of PIAS2beta speciﬁcally kills anaplastic carcinomas by mitotic catastrophe  \nReceived: 2 August 2022  \n\n| Accepted: 11 April 2024 |\n| --- |\n| |\n| Check for updates |\n\nJoana S. Rodrigues 1,14,15, Miguel Chenlo 1,15, Susana B. Bravo 2, Sihara Perez-Romero1, Maria Suarez-Fariña1, Tomas Sobrino 3,4, Rebeca Sanz-Pamplona5,6, Román González-Prieto 7,8,  \nManuel Narciso Blanco Freire9, Ruben Nogueiras 10, Miguel López 11  \n,  \nLaura Fugazzola12, José Manuel Cameselle-Teijeiro 13,16  & Clara V. Alvarez 1,16   \nThe E3 SUMO ligasePIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with high mortality. We show here that depletion of the PIAS2 beta isoform with a transcribed double-stranded RNA–directed RNA interference (PIAS2b-dsRNAi) speciﬁcally inhibits growth of ATC cell lines and patient primary cultures in vitro and of orthotopic patient-derived xenografts (oPDX) in vivo. Critically, PIAS2b-dsRNAi does not affect growth of normal or non-anaplastic thyroid tumor cultures (differentiated carcinoma, benign lesions) or cell lines. PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. PIAS2b depletion promotes mitotic catastrophe at prophase. High-throughput proteomics reveals the proteasome (PSMC5) and spindle cytoskeleton (TUBB3) to be direct targets of PIAS2b SUMOylation at mitotic initiation. These results identify PIAS2b-dsRNAi asa promising therapy for ATC and other aggressive anaplastic carcinomas.  \nThyroid carcinomas (TC) derived from follicular epithelium are the ﬁfth most common cancer in women, and the second in women aged 20–59. The majority of cases are differentiated TCs, either papillary TC (PTC, ∼85%) or follicular TC (FTC, ∼10%)1. Some of these TCs evolve to high-grade follicular cell-derived non-anaplastic thyroid carcinoma (differentiated high-grade thyroid carcinoma [DHGTC] and poorly differentiated thyroid carcinoma [PDTC]), which are more aggressive but still maintain some differentiation1,2. Anaplastic (undifferentiated) thyroid carcinoma (ATC) accounts for 1% of TC in the USA and is the most aggressive cancer in humans1,3. The 8th AJCC staging classiﬁes all ATCs as stage IV3–5. Patients are more likely to be female (F:M 2:1), aged 60 or older, and have a fast-growing  \nneck mass. Over half have metastatic disease at diagnosis.  \nATC patients die by 6 months after diagnosis, with a 100% diseasespeciﬁc mortality. Only extensive surgery with multimodal therapy offers any survival beneﬁt, but this comes at the cost of quality of life6. Adjuvant chemotherapy or radiotherapy is ineffective for long-term survival3.  \nRecently, an effort to apply precision therapy in ATC led to the approval of dabrafenib plus trametinib as a ﬁrst-line therapy, in a neoadjuvant setting combined with surgery for patients with ATC who have aBRAFV600E (BRAF+) mutation; this therapy extends lifespan by more than 1 year3,5. Unfortunately, only 25–40% of patients with ATCare BRAF+, and post-treatment can induce resistance through  \n1  \nIn general,  \nA full list of afﬁliations appears at the end of the paper. e-mail: josemanuel.cameselle@usc.es; [clara.alvarez@usc.es](clara.alvarez@usc.es)  \nsubsequent additional BRAF mutations7,8. Ongoing clinical trials test other combinations with surgery9–12.  \nATCs usually conserve expression of cytokeratins and patchy E-cadherin. Regarding thyroid-speciﬁc markers, ATC lose expression of NKX2-1 (TTF1), Na+/I − symporter (NIS), thyroglobulin (TG), and thyroperoxidase (TPO), but half of cases maintain PAX8 expression1,13,14. They present > 50% Ki67 index, are aneuploid, and have an increase","cbCaikeUNCfXk2oB","https://ap.wps.com/l/cbCaikeUNCfXk2oB","pdf",10368225,"English","# Study overview\n## PIAS2 expression in thyroid cancer\n## PIAS2b-dsRNAi anti-tumor effects\n## Specificity toward anaplastic cancers\n## Mechanistic basis: mitotic catastrophe\n## Proteomics-identified targets\n## Context: ATC clinical burden and current therapies\n## Thyroid-cancer models and culture resources","[{\"question\":\"What is the therapeutic target in this study?\",\"answer\":\"The study targets the PIAS2β isoform using PIAS2b-dsRNAi to deplete PIAS2β in anaplastic thyroid carcinoma models.\"},{\"question\":\"Does PIAS2b-dsRNAi affect normal or non-anaplastic thyroid cells?\",\"answer\":\"No. PIAS2b-dsRNAi does not affect growth of normal thyroid or non-anaplastic thyroid tumor cultures and cell lines in the reported results.\"},{\"question\":\"How does PIAS2b depletion kill anaplastic cancer cells mechanistically?\",\"answer\":\"PIAS2b depletion promotes mitotic catastrophe at prophase by disrupting proper mitotic spindle and centrosome assembly, with PSMC5 and TUBB3 identified as direct SUMOylation targets at mitotic initiation.\"}]","dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe | PDF",1790029845,76,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a945db09da522acb766ea4c6e7c0b9f.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/833a9733731340b059b30a8f4cde3cc3.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f68fb184d6afced71037dabaf7923249.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a6c77087efe373e4eb450e733f67cce.webp",980,1301]